2024-03-28T20:15:32Zhttps://riubu.ubu.es/oai/requestoai:riubu.ubu.es:10259/52432021-11-02T12:06:20Zcom_10259_4725com_10259_5086com_10259_2604col_10259_4726
González López, Tomás José
Sánchez González, Blanca
Jarque, Isidro
Bernat, Silvia
Fernández Fuertes, Fernando
Caparrós, Isabel
Soto, Inmaculada
Fernández Rodríguez, Angeles
Bolaños, Estefanía
Pérez Rus, Gloria
Pascual, Cristina
Hernández Rivas, José Angel
López Ansoar, Elsa
Gómez Nuñez, Marta
Martínez Robles, Violeta
Olivera, Pavel
Yera Cobo, Maria
Peñarrubia, María Jesús
Fernández Miñano, Carmen
Cabo, Erik
Martínez Badas, María Paz
Perdomo Hernández, Germán M.
García Frade, Luis Javier
2020-03-13T11:04:12Z
2020-03-13T11:04:12Z
2020-03
0902-4441
http://hdl.handle.net/10259/5243
10.1111/ejh.13370
1600-0609
Background
Eltrombopag is useful for immune thrombocytopenia (ITP). However, results of clinical trials may not accurately mirror clinical practice reality. Here we evaluated eltrombopag for primary and secondary ITP in our ≥65‐year‐old population.
Methods
A total of 106 primary ITP patients (16 with newly diagnosed ITP, 16 with persistent ITP, and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases, and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated.
Results
Median age of our cohort was 76 (interquartile range, IQR, 70‐81) years. 75.9% of patients yielded a platelet response including 66.2% complete responders. Median time to platelet response was 14 (IQR, 8‐21) days. Median time on response was 320 (IQR, 147‐526) days. Sixty‐three adverse events (AEs), mainly grade 1‐2, occurred. The most common were hepatobiliary laboratory abnormalities (HBLAs) and headaches. One transient ischemic attack in a newly diagnosed ITP and two self‐limited pulmonary embolisms in secondary ITP were the only thrombotic events observed.
Conclusion
Eltrombopag showed efficacy and safety in ITP patients aged ≥65 years with primary and secondary ITP. However, efficacy results in LPD‐ITP were poor. A relatively high number of deaths were observed.
application/pdf
eng
John Wiley & Sons
European Journal of Haematology. 2020, V. 104, n. 3, p. 259-270
https://doi.org/10.1111/ejh.13370
elderly
eltrombopag
immune thrombocytopenia
primary
secondary
Sistema cardiovascular-Enfermedades
Cardiovascular system-Diseases
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia
info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
info:eu-repo/semantics/openAccess
European Journal of Haematology
104
3
259
270